News & updates.
Product launches, regulatory milestones, partnerships, and research from HeartSciences.
Cibolo Health Designates MyoVista Insights as Endorsed ECG Management Platform for 123 Hospitals
Cibolo Rural Health Networks has selected MyoVista Insights as its endorsed ECG management platform for the 123 independent hospitals across six states inside its high-value networks.
Read storyHeartSciences Announces FDA 510(k) Submission for MyoVista wavECG Device
The MyoVista wavECG device — a 12-lead ECG platform designed to host AI-ECG algorithms — has been submitted to the FDA for 510(k) premarket clearance.
Read storyMajor Upgrade to MyoVista Insights Platform — Commercial Launch Version 1.1
Version 1.1 ships a redesigned worklist, longitudinal ECG comparison overlays, and a faster waveform caliper — built around feedback from early-adopter clinicians.
Read storyMyoVista Insights AI-ECG Algorithm for Aortic Stenosis Receives FDA Breakthrough Device Designation
The FDA granted Breakthrough Device Designation to a MyoVista Insights algorithm targeting earlier detection of aortic stenosis.
Read storyAI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Centers for Medicare & Medicaid Services have published reimbursement assignment for AI-ECG analysis services using MyoVista technology.
Read storyHeartSciences and Rutgers University Announce Multi-Year AI-ECG Collaboration
A multi-year collaboration with Rutgers Robert Wood Johnson Medical School expands the AI-ECG algorithm pipeline and clinical validation footprint.
Read story